ClinicalTrials.gg

Program

AZD4954

A development code. Also written as “[14C]AZD4954 Oral Solution”, “AZD4954 film-coated tablet” and “[14C]AZD4954 Solution for Infusion”.

Its studies are mostly in Dyslipidemias, led by AstraZeneca.

Furthest: phase 1, since May 19, 20253 company-led studies, 2 open or runningNext primary completion: Mar 17, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca32 open or runningphase 1since May 19, 2025May 19, 2025Mar 17, 2027phase 1 · NCT07812077
  • Named in AstraZeneca’s own pipeline as AZD4954, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: quotient-sciences.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2025First study: phase 1 study in DyslipidemiasFirst studyNCT06980428 · 171 planned · United States
  2. Mar 31, 2026Phase 1 study in DyslipidemiasNCT07513571 · 31 enrolled · United States
  3. Sep 4, 2026Phase 1 study in Healthy ParticipantsNCT07812077 · 16 planned · United Kingdom
  4. Nov 13, 2026Primary completion moved from 2026-12-17 to 2027-03-17Date moved laterphase 1 · +3 months · NCT07812077

Ahead

  1. Mar 17, 2027Primary completion: phase 1 study in Healthy ParticipantsNCT07812077
  2. Apr 9, 2027Primary completion: phase 1 study in DyslipidemiasNCT06980428

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07812077Healthy Participants · United Kingdom1RecruitingMar 17, 202716
NCT07513571Dyslipidemias · United States1CompletedJul 8, 202631
NCT06980428Dyslipidemias · United States1RecruitingApr 9, 2027171

How it is read

Names in the registry

  • “AZD4954”, 2 entries
  • “[14C]AZD4954 Oral Solution”, 1 entry
  • “AZD4954 film-coated tablet”, 1 entry
  • “[14C]AZD4954 Solution for Infusion”, 1 entry

Codes read as this program: AZD4954.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.